Detraleks Tab n / a film about 1000mg 60 pieces

Description

Composition
Active substance:
Purified, micronized flavonoid fraction, calculated as dry substance, 1000,00 mg consisting of: diosmin 900 mg (90%), flavonoids, hesperidin, based on 100 mg (10%).
Excipients:
Purified Water 40.00 mg of gelatin, 62.00 mg magnesium stearate 8.00 mg 124.00 mg microcrystalline cellulose, carboxymethyl starch sodium type A 54.00 mg Talc 12.00 mg.
Weight of tablet core 1340 mg 1).
Sheath Film: Sodium lauryl sulfate 0.130 mg, premix for film coating an orange-pink OY-S-8761, consisting of: glycerol 1,628 mg Hypromellose 27.039 mg Macrogol 6000 0.651 mg magnesium stearate 1.628 mg, colorant Iron oxide red 0.211 mg , 5.205 mg of titanium dioxide, iron oxide yellow colorant 0.633 mg.
Excipient polishing tablets: Macrogol 6000 1.300 mg.
Weight of tablets, film-coated 1378.425 mg.
1) Considering the average humidity of purified, micronized flavonoid fraction – 4% (or 40 mg per tablet), the quantity of substance per tablet – 1040.00 mg.
Description:
Oval tablets, film-coated orange-pink color with Valium on both sides.
Kind of pills on a break from a pale yellow to yellow, non-uniform structure.
Product form:
Tablets, film-coated 1000 mg
10 tablets in a blister (PVC / Al). 6 blisters with instructions for use in veditsinskomu pack carton with the first opening control (if necessary).
Contraindications
Hypersensitivity to the active ingredients or excipients included in the preparation.
We do not recommend the drug to nursing women.
Dosage
1000 mg
Indications
Detraleks® indicated for the treatment of chronic venous disease symptoms (elimination and the relief of symptoms).
Therapy symptoms venous-lymphatic insufficiency:
– pain;
– spasms of the lower limbs;
– a feeling of heaviness and fullness in the legs;
– “tired” legs.
Therapy manifestations of venous-lymphatic insufficiency:
– swelling of the lower extremities;
– trophic changes of the skin and subcutaneous tissue;
– venous trophic ulcers.
Symptomatic treatment of acute and chronic hemorrhoids.
Interaction with other drugs
Clinical studies of drug interactions Detraleks preparation with other drugs was conducted.
To date, no reports of any cases of drug interactions.
Overdose
Overdose is not described.
If overdose seek immediate medical attention.
pharmachologic effect
Pharmacological group:
Venotoniziruyuschee and venoprotektornoe means.
Pharmacodynamics:
Detraleks® has angioproteguoe and venotonic properties.
The drug reduces the extensibility of the veins and venous stasis, reduces the permeability of capillaries and improves their resistance. Results of clinical studies confirm the pharmacological activity of the drug against venous hemodynamic indices.
A statistically significant dose-dependent effect of the drug was demonstrated Detraleks® following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimum ratio of “dose-effect” is observed when receiving 1000 mg per day.
Detraleks® increases venous tone: using venous occlusion plethysmography been shown to decrease venous emptying time. Patients with signs of pronounced microcirculatory disorders, after therapy with Detraleks® observed (statistically significant compared to placebo), increase in capillary resistance estimated by angiostereometrii.
Detraleks® proved the therapeutic efficacy of the drug in the treatment of chronic diseases of the lower limbs, as well as in the treatment of hemorrhoids.
Pharmacokinetics:
Main drug selection occurs in the faeces. The urine, on average, about 14% output the received amount of the drug.
half-life is 11 hours.
The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.
Pregnancy and breast-feeding
Pregnancy
Animal experiments did not reveal any teratogenic effects.
Until now there has been no reports of adverse effects when using the drug in pregnant women.
Lactation
Due to lack of data on the excretion of the drug in breast milk, breast-feeding women are not recommended to take the drug.
Effects on reproduction
Reproductive toxicity studies have not shown effects on reproductive function in rats of both sexes.
Conditions of supply of pharmacies
Available without prescription.
side effects
Side effects of the drug Detraleks® observed in clinical trials were mild degree. Advantageously marked disorders of the gastrointestinal (diarrhea, dyspepsia, nausea, vomiting).
At the time of taking the drug Detraleks® reported the following side effects in the form of the following gradation: very common (> 1/10); common (> 1/100,
special instructions
– Before you start taking the drug Detraleks®, it is recommended to consult a doctor.
– In acute hemorrhoids Detraleks® use of the drug does not replace specific treatment other anal disorders.
The duration of treatment should not exceed the time specified in the “Method of administration and dose.” In that case, if the symptoms do not disappear after the recommended course of treatment, should be examined by a proctologist, who will pick up further therapy.
– In the presence of venous circulation disorders maximum effect of treatment provided by a combination therapy with a healthy (balanced) way of life: it is desirable to avoid a long stay in the sun longer stay on his feet, and recommended reduction of overweight. Hiking and, in some cases, wearing special stockings help to improve blood circulation.
Immediately contact your doctor if you are in the process of treating your condition worse or no improvement.
Effects on ability to drive and perform work requiring a high rate of mental and physical reactions
Clinical studies on the effect of the drug Detraleks on ability to drive and perform work requiring a high rate of mental and physical reactions, have been conducted. However, on the basis of the available safety data, we can conclude that Detraleks no effect (no significant effect) on these processes.
Storage conditions
At a temperature of not higher than 30 ° C.
Keep out of the reach of children.
Dosing and Administration
Inside.
The recommended dose for venous-lymphatic insufficiency – one tablet per day, preferably in the morning at mealtimes. The tablets should be swallowed with water.
Risk on the tablet is intended solely for the division in order to facilitate swallowing.
The duration of treatment may last several months (up to 12 months). In the case of recurrence of symptoms, on doctor’s advice, treatment can be repeated.
The recommended dose for acute hemorrhoid – 3 tablets per day (one tablet in the morning, afternoon and night) for 4 days, then 2 tablets per day (one tablet in the morning and evening) during the next 3 days.
The recommended dose for chronic hemorrhoids – 1 tablet per day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist